首頁 > 市場調查報告書 > 醫療設備

婦科治療

市場調查報告書

商品編碼

1622106

全球子宮肌瘤治療市場規模（依治療類型、類型、最終用戶、地區、範圍和預測）

Global Uterine Fibroids Treatment Market Size By Treatment Type, By Type, By End Users, By Geographic Scope And Forecast

出版日期: 2024年07月14日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

子宮肌瘤治療的市場規模及預測

2023 年子宮肌瘤治療市場規模價值 48.7 億美元，預計到 2031 年將達到 107.1 億美元，2024 年至 2031 年的複合年增長率為 9.30%。子宮肌瘤治療的特點是採用多種解決方案來治療子宮內的非癌性生長（稱為子宮肌瘤）。有多種治療方法可供選擇，從聚焦超音波等微創手術到肌瘤切除術等大型外科手術，可有效治療子宮肌瘤並改善患者的整體生活品質。

女性將透過緩解與子宮肌瘤和相關焦慮相關的身體症狀而直接從這個市場受益。同時，為醫院和診所等醫療機構提供專門的設備和程序將增強他們解決這一常見婦女健康問題的能力。

子宮肌瘤是子宮最常見的良性腫瘤，大小不一，影響約 20% 至 40% 的育齡婦女。受影響個體所經歷的症狀包括月經量過多、骨盆疼痛、頻尿和其他不適。治療方法包括荷爾蒙標靶藥物、栓塞、MRI引導的聚焦超音波手術（FUS）以及某些情況下的子宮切除術，影響著全世界數百萬名女性。

子宮肌瘤治療的全球市場動態

影響子宮肌瘤治療市場的關鍵市場動態

主要市場驅動因子

子宮肌瘤盛行率不斷上升：

研究發現，隨著女性年齡的增長，受生育延遲、肥胖率上升和診斷技術進步等因素的影響，子宮肌瘤的診斷率增加。

對微創手術的需求不斷增加：

子宮動脈栓塞術和聚焦超音波消融術等恢復時間更快的微創治療越來越被女性視為傳統手術的理想替代方案。

技術進步：

子宮肌瘤治療領域的技術不斷創新，帶來了新的、侵入性更小的治療方法的出現，例如MRI引導下的聚焦超音波治療和雷射消融，提供了更安全、更有效的治療選擇。

增加獲得醫療保健的機會：

一些地區不斷擴大的保險覆蓋率和政府措施正在擴大診斷和治療的可及性，有助於擴大市場並滿足更廣泛患者群體的醫療保健需求。

主要問題

成本障礙：

與手術和專用設備相關的費用是重大障礙，阻礙了人們獲得所需的護理，特別是對於保險覆蓋有限的社區和社會經濟地位較低的個人。

意識課題：

女性和醫療保健專業人員對子宮肌瘤和可用的治療方案的瞭解有限，可能會導致延遲診斷，阻礙早期幹預工作並加劇子宮肌瘤的影響。

限制存取：

觀察到合格婦科醫生和專科治療中心分佈不均，尤其是在農村地區，給患者尋求治療帶來了障礙，並限制了他們接受適當醫療護理的能力。

與專家的接觸有限：

合格婦科醫生和專科治療中心的缺乏，尤其是在農村地區，被認為是患者獲得治療的一大障礙。

主要趨勢

微創手術：

UAE、MRgFUS 和機器人手術等領域的成長是由人們對微創治療選擇的偏好所推動的，反映了以患者為中心的護理的更廣泛趨勢。

個人化您的治療：

根據年齡、生育目標和症狀嚴重程度等個人因素制定護理計劃，正在推動精準醫療方法，從而改善治療結果和患者滿意度。

技術進步：

人工智慧診斷、機器人輔助手術和生物相容性材料的發展有可能提高準確性、降低風險並縮短恢復時間，代表子宮肌瘤治療技術的重大進步。

生育力保護重點：

對子宮肌瘤治療的需求不斷增長，以盡量減少對生育能力的影響，例如保留卵巢組織的肌瘤切除術，這導致患者越來越重視保留生育能力的選擇。

Uterine Fibroids Treatment Market size is valued at USD 4.87 Billion in 2023 and is projected to reach USD 10.71 Billion by 2031, growing at a CAGR of 9.30% from 2024 to 2031. The Uterine Fibroids Treatment is characterized by a variety of solutions tailored to address non-cancerous growths, known as uterine fibroids, within the uterus, which are often associated with discomfort, heavy bleeding, and fertility concerns for affected women. A diverse toolbox of options, ranging from minimally invasive procedures like focused ultrasound to more extensive surgical interventions such as myomectomy, is offered by this market, to effectively manage fibroids and enhance the overall quality of life for patients.

Women are directly benefited by this market through the alleviation of physical symptoms and related anxieties associated with fibroids, while specialized equipment and procedures are provided to healthcare institutions like hospitals and clinics, thereby enhancing their ability to address this prevalent women's health issue.

Uterine fibroids, the most common benign tumors in the uterus, are characterized by varying sizes and affect approximately 20%-40% of women during their reproductive years. Symptoms, including heavy menstrual bleeding, pelvic pain, frequent urination, and other discomforts, are experienced by affected individuals. Treatment approaches, encompassing hormone-targeting medications, embolization, MRI-guided focused ultrasound surgery (FUS), and in some cases, hysterectomy, impact millions of women worldwide.

Global Uterine Fibroids Treatment Market Dynamics

The key market dynamics that are shaping the Uterine Fibroids Treatment Market include:

Key Market Drivers

Increased Prevalence of Uterine Fibroids:

A growing diagnosis rate of uterine fibroids among women as they age is indicated by research, influenced by factors such as delayed childbearing, escalating obesity rates, and enhanced diagnostic methodologies.

Growing Demand for Minimally Invasive Procedures:

Less invasive and speedier recovery alternatives, including uterine artery embolization and focused ultrasound ablation, are increasingly favored by women as preferable alternatives to conventional surgeries.

Advancements in Technology:

Continuous innovation in the realm of uterine fibroid treatment has led to the emergence of novel, minimally invasive procedures like MRI-guided focused ultrasound and laser ablation, offering safer and more efficacious therapeutic options.

Expansion of Healthcare Accessibility:

Enhanced insurance coverage and governmental initiatives in select regions are widening the accessibility to both diagnosis and treatment, propelling market expansion and catering to the healthcare needs of a broader patient demographic.

Key Challenges

Cost Barriers:

The cost associated with procedures and specialized equipment is seen as a significant hindrance, particularly in regions with limited insurance coverage or for individuals with lower socioeconomic status, thereby impeding access to necessary treatment.

Awareness Challenges:

Limited understanding of fibroids and the available treatment options among both women and healthcare professionals can result in delayed diagnosis and hinder efforts for early intervention, exacerbating the impact of the condition.

Access Limitations:

Disparities in the distribution of qualified gynecologists and specialized treatment centers, particularly evident in rural areas, are observed to create obstacles for patients seeking care, thus limiting their ability to access appropriate medical attention.

Limited Access to Specialists:

Unequal availability of qualified gynecologists and specialized treatment centers, particularly pronounced in rural areas, is noted to contribute to barriers in accessing care for patients.

Key Trends

Minimally Invasive Procedures:

Growth in segments like UAE, MRgFUS, and robotic surgery is driven by a preference for less invasive options, reflecting a broader trend toward patient-centered care.

Treatment Personalization:

Precision medicine approaches are promoted through tailoring treatment plans based on individual factors such as age, fertility goals, and symptom severity, enhancing treatment efficacy and patient satisfaction.

Technological Advancements:

Precision improvement, risk reduction, and potential recovery time shortening are observed with ongoing developments in AI-powered diagnostics, robotic-assisted surgery, and biocompatible materials, signifying significant strides in fibroid treatment technology.

Fertility Preservation Focus:

An increasing demand for fibroid treatments minimizing the impact on reproductive potential, like myomectomy with ovarian tissue preservation, highlights a growing emphasis on preserving fertility options for patients.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Uterine Fibroids Treatment Market Regional Analysis

Here is a more detailed regional analysis of the Uterine Fibroids Treatment Market:

North America

A high prevalence of uterine fibroids in North America, particularly the United States, is observed compared to other regions, with factors like lifestyle choices and improved diagnostic techniques being attributed.

The financial burden of fibroid treatment for many individuals is eased by the well-developed healthcare infrastructure in North America, including advanced medical facilities and skilled specialists, along with widespread health insurance coverage.

Continuous innovation in the development of novel treatment options for uterine fibroids is driven by North America's role as a hub for research and development, positioning regional companies as market leaders. This enables the region to hold a major share in the market.

Asia Pacific

A rise in uterine fibroid prevalence in the Asia Pacific is anticipated due to factors such as delayed childbearing and increasing obesity rates, prompting earlier diagnosis and treatment seeking among women and healthcare professionals.

Investments in healthcare infrastructure, including the establishment of more hospitals and clinics equipped for advanced fibroid treatments, are being made in many Asian countries as a result of rapid economic development, with rising disposable incomes facilitating this development.

The Asia Pacific region's vast population size, particularly in countries like China and India, presents a significant untapped market for fibroid treatment solutions, attracting attention from global players and driving market growth as healthcare access and affordability increase.

Global Uterine Fibroids Treatment Market Segmentation Analysis

The Global Uterine Fibroids Treatment Market is segmented on the basis of Treatment Type, Type, End Users, and Geography.

Uterine Fibroids Treatment Market, By Treatment Type

Surgical
Myomectomy
Endometrial Ablation
Hysterectomy
Hormonal
Progestins
GnRH Agonists
MRI-guided Focused Ultrasound Surgery (FUS)
Embolization
Others

Based on Treatment Type, The market is segmented into Surgical, Hormonal, Embolization, MRI-guided Focused Ultrasound Surgery (FUS), and Others. Of these, the largest market share is commanded by the surgical segment, primarily due to its effectiveness in addressing fibroids through procedures like myomectomy and hysterectomy. Patients are provided with tangible relief from symptoms and their quality of life is improved through direct removal or ablation of fibroids offered by surgical interventions. The significance of surgical options in managing uterine fibroids is underscored by this dominance, highlighting their widespread acceptance among patients and healthcare providers.

Uterine Fibroids Treatment Market, By Type

Submucosal Fibroids
Intramural Fibroids
Pedunculated Fibroids
Subserosal Fibroids

Based on Type, The market is segmented into Submucosal Fibroids, Intramural Fibroids, Pedunculated Fibroids, and Subserosal Fibroids. Among the types, the highest market share in the Uterine Fibroids Treatment Market is typically held by intramural fibroids. This is because intramural fibroids are the most common type, growing within the muscular wall of the uterus. The pain caused by these are shifting the focus on various treatment options depending on severity and patient preferences.

Uterine Fibroids Treatment Market, By End Users

Hospitals
Clinics
Ambulatory Surgical Centers
Gynecologists

Based on End Users, The market is segmented into Hospitals, Clinics, Ambulatory Surgical Centers, and Gynecologists. The highest market share in the Uterine Fibroids Treatment Market is typically held by hospitals. This is primarily because hospitals function as primary healthcare facilities where a wide range of medical services, including fibroid treatments, are provided. Hospitals are often equipped with specialized departments and equipment dedicated to gynecological procedures, making them a preferred choice for patients seeking comprehensive fibroid treatment.

Key Players

The "Global Uterine Fibroids Treatment Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as
Boston Scientific Corporation, GE Healthcare, Siemens Medical Solutions, Cooper Surgical, and F. Hoffmann-La Roche Ltd.

Our market analysis includes a section specifically devoted to such major players, where our analysts give an overview of each player's financial statements, product benchmarking, and SWOT analysis. Key development strategies, market share analysis, and market positioning analysis of the aforementioned players globally are also included in the competitive landscape section.

Uterine Fibroids Treatment Market Recent Developments
In October 2023, a partnership was formed between Siemens Healthineers AG and IZI Medical Products to integrate the Fibroid Finder software with the Acessa procedure, to enhance treatment planning for fibroids.
In October 2023, the Sono Site iViz ultrasound system was launched by Olympus Corporation, featuring enhanced functionalities designed for diagnosing and guiding minimally invasive fibroid treatments.
In October 2023, CE Mark approval was received by Boston Scientific Corporation for its EMPOWER MRgFUS system, thereby expanding its portfolio of minimally invasive fibroid treatment options in Europe.

1 INTRODUCTION OF GLOBAL UTERINE FIBROIDS TREATMENT MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL UTERINE FIBROIDS TREATMENT MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL UTERINE FIBROIDS TREATMENT MARKET, BY TREATMENT TYPE

5.1 Overview
5.2 Surgical
- 5.2.1 Myomectomy
- 5.2.2 Endometrial ablation
- 5.2.3 Hysterectomy
5.3 Hormonal
- 5.3.1 Progestins
- 5.3.1 GnRH agonists
5.4 MRI-guided Focused Ultrasound Surgery (FUS)
5.5 Embolization
5.6 Others

6 GLOBAL UTERINE FIBROIDS TREATMENT MARKET, BY TYPE

6.1 Overview
6.2 Submucosal Fibroids
6.3 Intramural Fibroids
6.4 Pedunculated Fibroids
6.5 Subserosal Fibroids

7 GLOBAL UTERINE FIBROIDS TREATMENT MARKET, BY END USERS

7.1 Overview
7.2 Hospitals
7.3 Clinics
7.4 Ambulatory Surgical Centers
7.5 Gynecologists

8 GLOBAL UTERINE FIBROIDS TREATMENT MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East And Africa

9 GLOBAL UTERINE FIBROIDS TREATMENT MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Boston Scientific Corporation
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 GE Healthcare
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Siemens Medical Solutions
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Cooper Surgical
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 F. Hoffmann-La Roche Ltd.
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments